Tennantcates7892

These studies assessed the efficacy and safety of fevipiprant, an oral antagonist of the prostaglandin D

(PGD

) receptor (DP

), compared with placebo when added to standard-of-care (SoC) asthma therapy in patients with uncontrolled asthma.

ZEAL-1 (NCT03215758) and ZEAL-2 (NCT03226392) are two replicate, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group studies in which fevipiprant 150mg once daily (o.d.) or placebo was added to SoC asthma therapy in patients aged ≥12 years with uncontrolled asthma. Primary endpoint change from baseline in pre-dose forced expiratory volume in 1s (FEV

) after 12 weeks' treatment. Key secondary endpoints daytime asthma symptom score, short-acting β-agonist (SABA) use and Asthma Quality-of-Life Questionnaire (AQLQ+12) score after 12-weeks treatment.

662 patients in ZEAL-1 and 685 patients in ZEAL-2 completed the treatment period. In ZEAL-1, the least squares (LS) mean change from baseline in pre-dose FEV

was 112mL in fevipiprant vs 71mL in placebo group (difference [∆]41mL; 95% CI -6, 88; adjusted p-value 0·088). In ZEAL-2, the LS mean change in pre-dose FEV

was 126mL and 157mL in the fevipiprant and placebo groups, respectively (∆-31mL; 95% CI -80, 18; adjusted p-value 0·214). For both studies, there were no statistically significant differences in the key secondary objectives between the treatment groups.

The ZEAL studies did not demonstrate significant improvement in lung function or other clinical outcomes. These results suggest that DP

receptor inhibition with fevipiprant is not effective in the studied patient population.

The ZEAL studies did not demonstrate significant improvement in lung function or other clinical outcomes. These results suggest that DP2 receptor inhibition with fevipiprant is not effective in the studied patient population.

Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size, facilitate resection, and reduce functional and aesthetic consequences of surgery. The VISMONEO study assessed efficacy and safety of vismodegib in neoadjuvant treatment of laBCC.

VISMONEO (NCT02667574) is an open-label, noncomparative, multicenter, phase 2 study. Patients with ≥1 histologically confirmed facial BCC, inoperable or operable with functional or major aesthetic sequelae risk, were included. Oral vismodegib 150mg was administered once daily for 4 to 10 months before planned surgery, which was performed once the best response under vismodegib was observed. Primary endpoint was percentage of patients with BCC with tumor downstaging following surgical resection after neoadjuvant vismodegib. Downstaging was definednn-La Roche Ltd.

Our objective is to examine whether residential racial segregation may be constraining capacities for social distancing thus leaving African Americans potentially more exposed to contracting COVID-19. We hypothesized that residential racial segregation constrains African Americans' spatial mobility when the whole population is locked down but increases their need for moving under reopening orders.

We employ a Black/White dissimilarity index as our independent variable and county-level mobility ratios as our dependent variable. Using generalized estimating equations for longitudinal data, we analyzed the effects of Black/White segregation on population mobility by counties across the United States from March 8 to August 7, 2020 under two different COVID-19 related policy conditions lockdown and reopening.

While higher county-wide levels of segregation were significantly associated with decreased mobility under lockdown and stay-at-home orders, we found that this relationship between segregation and mobility dissipated under reopening orders.

Investigating the effects of health policy without considering differing effects due to structural racism will likely ignore complexities that may create unintended consequences of health policy. Our conclusions suggest African Americans may face structural limitations to effective social distancing as evidenced by higher rates of mobility after reopening policies go into effect.

Investigating the effects of health policy without considering differing effects due to structural racism will likely ignore complexities that may create unintended consequences of health policy. Tricaine methanesulfonate Our conclusions suggest African Americans may face structural limitations to effective social distancing as evidenced by higher rates of mobility after reopening policies go into effect.

Neonatal hypothermia is a common source of morbidity and mortality in low resource settings. We developed the Dream Warmer, a low cost, re-usable non-electric infant warmer to prevent and treat hypothermia.

We conducted a cluster-randomized stepped-wedge trial. The primary aim was to assess the effect on overall euthermia rates of introducing the warmer compared to standard of care in rural Rwandan hospitals. The secondary aims were to assess effects of warmer introduction on mortality, as well as the safety and feasibility of the warmer. Ten district hospitals participated in the study from November 19th 2019 to July 15th 2020. Patients were eligible to use the warmer if they were 1) hypothermic (temp < 36·5 °C) or 2) or at risk of hypothermia (weight < 2·5kg or estimated post menstrual age < 35 weeks) when Kangaroo Mother Care was not available. An encounter was defined as the data from an individual infant on a single day. Trial of a Non Electric Infant Warmer for Prevention and Treatment of Hd rates of euthermia with no associated safety concerns.

The proportion of incident cases of HPV-attributable cancers is highest in the low- and middle-income countries (LMICs) but many are yet to initiate HPV vaccination programs. This meta-analysis was performed to assess the uptake of HPV vaccination in LMICs at the beginning of the global strategy to eliminate cervical cancer and describes the gaps and challenges.

A systematic search was conducted in PubMed, EMBASE, Scopus, Web of Science, and CENTRAL databases for observational studies that reported the uptake of HPV vaccination until October 2020. The meta-analysis was done using a random-effects model to assess the pooled estimate of HPV uptake. CRD42021218429.

During 2008-2020, an estimated 3.3 million females received at least one dose of HPV vaccine with 61.69% of the target population vaccinated. In countries with high uptake, the pooled estimate of uptake was higher in females than males (45.48% vs 8.45%) and showed significant decline in 2015-2020 compared to 2006-2014 (89.03% vs 41.48%). In countries with low uptake, the estimate of uptake was low in both males and females (5.